Evidence that enzyme-generated aromatic Michael acceptors covalently modify the nucleotide-binding site of 3 alpha-hydroxysteroid dehydrogenase.
The non-steroidal allylic and acetylenic alcohols 1-(4'-nitrophenyl)prop-2-en-1-ol (I) and 1-(4'-nitrophenyl)prop-2-yn-1-ol (II) are oxidized by homogeneous 3 alpha-hydroxysteroid dehydrogenase to the corresponding alpha beta-unsaturated ketones 1-(4'-nitrophenyl)prop-2-en-1-one (III) and 1-(4'-nitrophenyl)prop-2-yn-1-one (IV), which then inactivate the enzyme selectively with high affinity; low effective partition ratios are observed for the parent alcohols [Ricigliano & Penning (1989) Biochem. J. 262, 139-149]. Inactivation of 3 alpha-hydroxysteroid dehydrogenase by compound (I) displays an NAD+ concentration optimum. Scavenging experiments indicate that the enzyme-generated inactivators (III) and (IV) alkylate the enzyme via a release-and-return mechanism. Several lines of evidence suggest that compounds (III) and (IV) covalently modify the NAD(P)(+)-binding site. First, micromolar concentrations of NAD(P)H offer substantial protection against enzyme inactivation mediated by Michael acceptors (III) and (IV). In these protection studies Kd measurements for NAD(P)H approached those measured by fluorescence titration of free enzyme. Secondly, under initial-velocity conditions compounds (III) and (IV) act essentially as competitive inhibitors of NAD+ binding, and as mixed competitive or non-competitive inhibitors against androsterone binding. Thirdly, enzyme inactivated with either compound (III) or compound (IV) fails to bind to NAD+ affinity columns (e.g. Affi-gel Blue). Under the same conditions of chromatography native enzyme and enzyme affinity-labelled at the steroid-binding site with 17 beta-bromoacetoxy-5 alpha-dihydrotestosterone is retained on the affinity column. A kinetic scheme that represents the inactivation of the homogeneous dehydrogenase by the enzyme-generated alkylators (III) and (IV) is presented.
Ricigliano
J W
JW
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104-6084.
Penning
T M
TM
D015096:3-Hydroxysteroid Dehydrogenases / Q000378:metabolism*; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); D000818:Animals; D001665:Binding Sites; D055598:Chemical Phenomena; D002621:Chemistry; D002846:Chromatography, Affinity / Q000379:methods; D013196:Dihydrotestosterone / Q000031:analogs & derivatives; D007700:Kinetics; D008297:Male; D008623:Mercaptoethanol / Q000494:pharmacology; D009243:NAD / Q000378:metabolism*; D009249:NADP / Q000378:metabolism; D009578:Nitrobenzenes / Q000494:pharmacology*; D009711:Nucleotides / Q000378:metabolism*; D010084:Oxidation-Reduction; D011500:Protein Synthesis Inhibitors; D051381:Rats; D011919:Rats, Inbred Strains; D014227:Triazines
D009578:Nitrobenzenes; D009711:Nucleotides; D011500:Protein Synthesis Inhibitors; D014227:Triazines; D013196:Dihydrotestosterone; D009243:NAD; C061576:1-(4'-nitrophenyl)-2-propen-1-ol; C065408:1-(4'-nitrophenyl)prop-2-en-1-one; C065409:1-(4'-nitrophenyl)prop-2-yn-1-one; D009249:NADP; C012842:Cibacron Blue F 3GA; D008623:Mercaptoethanol; C023562:dihydrotestosterone 17-bromoacetate; D015096:3-Hydroxysteroid Dehydrogenases; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)